Phase Ia/Ib Study of CKD-512 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumors

Inclusion Criteria: * Histologically confirmed advanced or metastatic solid tumors. * Progressive disease after or intolerance to standard therapy and no other effective therapeutic options available. * Measurable disease as defined in Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. * Suitable venous access for the study-required blood sampling, including PK and PD sampling. * Adequate clinical laboratory values and other measures Exclusion Criteria: * Active disease involvement of the central nervous system. * Any serious or life-threatening medical condition unrelated to cancer, psychiatric illness, drug or alcohol abuse, that could, in the Investigator's opinion, potentially interfere with the completion of treatment according to this protocol. * Systemic anticancer treatment within the protocol-specified period prior to the first dose. * History of any immune-related toxicity that lead to permanent discontinuation of prior anticancer therapy * Radiation therapy on a limited area is allowed until 4 weeks prior to the first dose of study drug, provided that the radiated lesion is clinically stable. * Prior treatment with investigational agents ≤21 days before the first dose of study drug(s).